Pfizer will raise the prices of 41 drugs in January, amid escalating Trump administration efforts to lower prescription drug prices and months after President Trump’s intervention forced the largest U.S. drugmaker to postpone planned cost increases.
The hikes, first reported by the Wall Street Journal, will affect 5 percent of the company’s total drug portfolio and will be offset with higher rebates and discounts, Pfizer said in a statement. The Trump administration is expected to try to overhaul the drug rebate program, an effort departing CEO Ian Read previously told investors would advance in 2018.
Recommended Stories
Print subscriber? Click here to login/register your account
Digital subscriber? Click here to login/register your account.